

Robaxin (methocarbamol)

COMMON BRAND NAMES

Robaxin Injection, Robaxin-750

THERAPEUTIC CLASS

Muscular analgesic (centrally acting)

DEA CLASS

RX

ADULT DOSAGE & INDICATIONS

Musculoskeletal Conditions

Adjunct for relief of discomfort associated w/ acute, painful musculoskeletal conditions

Oral:

≥16 Years:

Robaxin:

Initial: 3 tabs qid

Maint: 2 tabs qid

Robaxin-750:

Initial: 2 tabs qid

Maint: 1 tab q4h or 2 tabs tid

6g/day are recommended for the first 48-72 hrs; 8g/day may be administered for severe conditions. Thereafter, the dose can usually be reduce to approx 4g/day

Inj:

Moderate Symptoms:

Single 1g (10mL) dose IV/IM; administration of oral form will usually sustain relief initiated by the inj

Max: 3g/day for no more than 3 consecutive days

Severe Cases/Postop Conditions:

Single 1g (10mL) dose IV/IM; may administer additional doses of 1g q8h

Max: 3g/day for no more than 3 consecutive days

Tetanus

Inj:

1 or 2 vials directly into the tubing of the previously inserted indwelling needle; additional 10mL or 20mL may be added to infusion bottle so that a total of up to 30mL (3 vials) is given as initial dose

Repeat q6h until conditions allow for insertion of NG tube; crushed methocarbamol tabs suspended in water or saline may then be given through this tube

Total oral doses up to 24g/day may be required

PEDIATRIC DOSAGE & INDICATIONS

Tetanus

Inj:

Initial: 15mg/kg or 500mg/m²; repeat q6h prn

Max: 1.8g/m² for 3 consecutive days

Maint dose may be administered by inj into tubing or by IV infusion w/ an appropriate quantity of fluid

ADMINISTRATION

Oral/IV/IM route

Directions for IV Use

Inj may be administered undiluted at a max rate of 3mL/min or added to an IV drip of NaCl inj or D5 inj

One vial given as a single dose should not be diluted to more than 250mL for IV infusion
Do not refrigerate after mixing w/ IV infusion fluids
Avoid vascular extravasation of this hypertonic sol, which may result in thrombophlebitis
Patient should be in a recumbent position during and for at least 10-15 min following inj

Directions for IM Use

Not more than 5mL (1/2 vial) should be injected into each gluteal region
Inj may be repeated at 8-hr intervals, if necessary
When satisfactory relief of symptoms is achieved, it can usually be maintained w/ tabs
Not recommended for SQ administration

HOW SUPPLIED

Inj: 100mg/mL [10mL]; Tab: 500mg, 750mg

CONTRAINDICATIONS

(Inj) Renal pathology with injection due to propylene glycol content.

WARNINGS/PRECAUTIONS

May impair mental/physical abilities. May cause color interference in certain screening tests for 5-hydroxy-indoleacetic acid (5-HIAA) and vanillylmandelic acid (VMA). Caution in epilepsy with the inj. Inj rate should not exceed 3mL/min. Avoid extravasation with inj. Avoid use in women who are or may become pregnant and particularly during early pregnancy.

ADVERSE REACTIONS

Lightheadedness, dizziness, drowsiness, nausea, urticaria, pruritus, rash, conjunctivitis, nasal congestion, blurred vision, headache, fever, seizures, syncope, flushing.

DRUG INTERACTIONS

Additive adverse effects with alcohol and other CNS depressants. May inhibit effect of pyridostigmine; caution in patients with myasthenia gravis receiving anticholinergics.

PREGNANCY AND LACTATION

Category C, caution in nursing.

MECHANISM OF ACTION

Carbamate derivative of guaifenesin; not established, suspected to have CNS depressant with sedative and musculoskeletal relaxant properties.

PHARMACOKINETICS

Distribution: Plasma protein binding (46-50%). Found in breast milk. **Metabolism:** Via dealkylation, hydroxylation, and conjugation pathways.
Elimination: Urine; $T_{1/2}$ =1-2 hrs.

ASSESSMENT

Assess for renal/hepatic impairment, myasthenia gravis, seizures, pregnancy/nursing status, alcohol intake, and drug interactions.

MONITORING

Monitor for congenital and fetal abnormalities if taken during pregnancy, for color interference in certain screening tests for 5-HIAA using nitrosonaphthol reagent, and in screening tests for urinary VMA using Gitlow method.

PATIENT COUNSELING

Instruct to use caution while performing hazardous tasks. Warn to avoid alcohol or other CNS depressants. Instruct to notify physician if pregnant/nursing or if planning to become pregnant.

STORAGE

20-25°C (68-77°F), in tight container; excursions permitted to 15-30°C (59-86°F).